Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.46 |
| ▸ | METAP1 | P53582 | 1/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 12/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 11/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.40 |
| ▸ | ADORA2B | P29275 | 5/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | CASP6 | P55212 | 1/20 | 0.38 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3663184 | 0.77 | ADORA2A (0.47) | PDPK1CYP2A6METAP1ADORA2AADORA1 | |
| SCHEMBL31631304 | 0.77 | ADORA2A (0.47) | PDPK1CYP2A6METAP1ADORA2AADORA1 | |
| SCHEMBL15624391 | 0.76 | TDP1 (0.44) | HSP90AA1 | |
| SCHEMBL28020115 | 0.76 | PDPK1 (0.50) | PDPK1CYP2A6METAP1ADORA2AADORA1 | |
| SCHEMBL8567274 | 0.76 | PDPK1 (0.55) | PDPK1CYP2A6ADORA2AADORA1RAB9A | |
| SCHEMBL7430359 | 0.73 | CYP11B1 (0.47) | CYP2A6ADORA2ARAB9A | |
| SCHEMBL1274801 | 0.73 | LOXL2 (0.50) | PDPK1CYP2A6METAP1ADORA2AADORA1 | |
| SCHEMBL30416689 | 0.73 | TRIM24 (0.46) | PDPK1CYP2A6METAP1ADORA2AADORA1 | |
| SCHEMBL20571767 | 0.73 | TGFBR1 (0.50) | PDPK1CYP2A6METAP1ADORA2AADORA1 | |
| SCHEMBL28394717 | 0.73 | ADORA2A (0.44) | PDPK1CYP2A6METAP1ADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2585451-B1 | HETEROCYCLIC COMPOUNDS AS AGENTS FOR PEST CONTROL | BAYER IP GMBH (DE) | 2017-03-01 | — | — | EP | disclosed |
| EP-2914598-A1 | HEPATITIS C VIRUS INHIBITORS | Bristol-Myers Squibb Company (US) | 2015-09-09 | — | — | EP | disclosed |
| US-9044015-B2 | Heterocyclic compounds as pesticides | BAYER CROPSCIENCE AG (DE) | 2015-06-02 | — | — | US | disclosed |
| US-20140148471-A1 | Heterocyclic Compounds as Pesticides | BAYER CROPSCIENCE AG (DE) | 2014-05-29 | — | — | US | disclosed |
| WO-2014071007-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-05-08 | — | — | WO | disclosed |
| EP-2585451-A2 | HETEROCYCLIC COMPOUNDS AS AGENTS FOR PEST CONTROL | Bayer Intellectual Property GmbH (DE) | 2013-05-01 | — | — | EP | disclosed |
| US-20120165345-A1 | Heterocyclic compounds as pesticides | BAYER CROPSCIENCE AG (DE) | 2012-06-28 | — | — | US | disclosed |
| WO-2012000896-A2 | HETEROCYCLIC COMPOUNDS AS AGENTS FOR PEST CONTROL | BAYER CROPSCIENCE AG (DE) | 2012-01-05 | — | — | WO | disclosed |
| US-20080312255-A1 | PIPERDINE COMPOUNDS AND USES THEREOF-911 | ASTRAZENECA AB (SE) | 2008-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140148471-A1 | Heterocyclic Compounds as Pesticides | DDT, ACHE, PTMS | PDPK1 364/4885CYP2A6 777/4885METAP1 2286/4885 |
| US-20120165345-A1 | Heterocyclic compounds as pesticides | DDT, ACHE, PTMS | PDPK1 364/4885CYP2A6 777/4885METAP1 2286/4885 |
| US-20080312255-A1 | PIPERDINE COMPOUNDS AND USES THEREOF-911 | NISCH, PIR, QDPR | PDPK1 977/4885CYP2A6 630/4885METAP1 1132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.